Cargando…
Outcomes of Different Haploidentical Transplantation Strategies from the Taiwan Blood and Marrow Transplantation Registry
SIMPLE SUMMARY: Haploidentical hematopoietic stem cell transplantation haplo-HSCT is now increasingly recognized as a valid treatment for patients with hematologic malignancies. The two most noteworthy strategies are posttransplantation cyclophosphamide (PTCy) with or without anti-thymoglobulin and...
Autores principales: | Tsai, Xavier Cheng-Hong, Chen, Tzu-Ting, Gau, Jyh-Pyng, Wang, Po-Nan, Liu, Yi-Chang, Lien, Ming-Yu, Li, Chi-Cheng, Yao, Ming, Ko, Bor-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870072/ https://www.ncbi.nlm.nih.gov/pubmed/35205845 http://dx.doi.org/10.3390/cancers14041097 |
Ejemplares similares
-
Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
por: Al Malki, Monzr M., et al.
Publicado: (2022) -
Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan
por: Hung, Yu-Chin, et al.
Publicado: (2021) -
Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation
por: Sharma, Nidhi, et al.
Publicado: (2021) -
Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant
por: Xu, Lan-Ping, et al.
Publicado: (2017) -
Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
por: Munchel, Ashley, et al.
Publicado: (2011)